A5000045197- Cancer-related gene regulation
- Epigenetics and DNA Methylation
- Macrophage Migration Inhibitory Factor
- Histone Deacetylase Inhibitors Research
- Immune Cell Function and Interaction
- Immune cells in cancer
- Nanoplatforms for cancer theranostics
- Cancer Immunotherapy and Biomarkers
- T-cell and B-cell Immunology
- Cancer Research and Treatments
- Neurogenetic and Muscular Disorders Research
Purdue University West Lafayette
2020-2023
Abstract Although immunotherapies of tumors have demonstrated promise for altering the progression malignancies, been limited by an immunosuppressive tumor microenvironment (TME) that prevents infiltrating immune cells from performing their anticancer functions. Prominent among are myeloid-derived suppressor (MDSC) and tumor-associated macrophages (TAM) inhibit T via release cytokines engagement checkpoint receptors. Here, we explore properties MDSCs TAMs freshly isolated mouse human find...
Folate receptor delta (FRδ) has been used as a biomarker for regulatory T cells (Tregs), because its expression is limited to Tregs and ovum. Although FRδ unable bind folate, we have molecular docking software identify folate congener that binds with high affinity exploited this FRδ-specific ligand target attached drugs (imaging agents, immune activators, suppressors) specifically in murine tumor xenografts. Analysis of treated tumors demonstrates targeting Toll-like 7 agonist inhibits Treg...
Abstract Myeloid derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs) are two of the more immunosuppressive cell types in a microenvironment (TME). Although TAMs MDSCs can be converted from tumor-supporting to tumor-suppressing phenotypes by treatment with proinflammatory immune stimulants (e.g. TLR7 agonists) vitro, such strategies have proven too toxic vivo because their systemic activation cells. Therefore, for used reprogram system solid tumors, they must targeted...
<div>Abstract<p>Although immunotherapies of tumors have demonstrated promise for altering the progression malignancies, been limited by an immunosuppressive tumor microenvironment (TME) that prevents infiltrating immune cells from performing their anticancer functions. Prominent among are myeloid-derived suppressor (MDSC) and tumor-associated macrophages (TAM) inhibit T via release cytokines engagement checkpoint receptors. Here, we explore properties MDSCs TAMs freshly isolated...
<p>supplemental figure 1</p>
<p>supplemental figure 2</p>
<p>supplemental figure 5</p>
<p>supplemental figure 3</p>
<p>supplemental figure 4</p>
<p>Figure legends for supplemental figures</p>
<p>Supplemental Methods</p>
<p>Supplemental Methods</p>
<p>supplemental figure 1</p>
<p>supplemental figure 2</p>
<p>supplemental figure 3</p>
<p>Figure legends for supplemental figures</p>
<p>supplemental figure 5</p>
<p>supplemental figure 4</p>
<div>Abstract<p>Although immunotherapies of tumors have demonstrated promise for altering the progression malignancies, been limited by an immunosuppressive tumor microenvironment (TME) that prevents infiltrating immune cells from performing their anticancer functions. Prominent among are myeloid-derived suppressor (MDSC) and tumor-associated macrophages (TAM) inhibit T via release cytokines engagement checkpoint receptors. Here, we explore properties MDSCs TAMs freshly isolated...